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Abstract
During disease progression to AIDS, HIV-1 infected individuals become increasingly immunosuppressed and susceptible to
opportunistic infections. It has also been demonstrated that multiple subsets of dendritic cells (DC), including DC-SIGN(+)
cells, become significantly depleted in the blood and lymphoid tissues of AIDS patients, which may contribute to the failure
in initiating effective host immune responses. The mechanism for DC depletion, however, is unclear. It is also known that
vast quantities of viral envelope protein gp120 are shed from maturing HIV-1 virions and form circulating immune
complexes in the serum of HIV-1-infected individuals, but the pathological role of gp120 in HIV-1 pathogenesis remains
elusive. Here we describe a previously unrecognized mechanism of DC death in chronic HIV-1 infection, in which ligation of
DC-SIGN by gp120 sensitizes DC to undergo accelerated apoptosis in response to a variety of activation stimuli. The
cultured monocyte-derived DC and also freshly-isolated DC-SIGN(+) blood DC that were exposed to either cross-linked
recombinant gp120 or immune-complex gp120 in HIV(+) serum underwent considerable apoptosis after CD40 ligation or
exposure to bacterial lipopolysaccharide (LPS) or pro-inflammatory cytokines such as TNFa and IL-1b. Furthermore,
circulating DC-SIGN(+) DC that were isolated directly from HIV-1(+) individuals had actually been pre-sensitized by serum
gp120 for activation-induced exorbitant apoptosis. In all cases the DC apoptosis was substantially inhibited by DC-SIGN
blockade. Finally, we showed that accelerated DC apoptosis was a direct consequence of excessive activation of the pro-
apoptotic molecule ASK-1 and transfection of siRNA against ASK-1 significantly prevented the activation-induced excessive
DC death. Our study discloses a previously unknown mechanism of immune modulation by envelope protein gp120,
provides new insights into HIV immunopathogenesis, and suggests potential therapeutic approaches to prevent DC
depletion in chronic HIV infection.
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Introduction
HIV-1 envelope protein gp120 binds to CD4 and chemokine
receptors CCR5 or CXCR4 which are expressed by dendritic cells
(DC) and which facilitate viral entry into the cells [1]. HIV-1
gp120 is also readily shed from the maturing virions [2] and forms
immune complexes in the plasma of HIV-infected [HIV(+)]
individuals [3,4]; consequently only a tiny portion (,0.1%) of
circulating virions are actually infectious [5,6]. HIV-1 gp120
additionally binds to DC-specific ICAM-grabbing non-integrin
(DC-SIGN), initiating an intracellular signalling cascade that
promotes viral infection and dissemination to T cells [7,8]. A
subset of CD14(+)DC-SIGN(+) DC has been identified in blood,
which can bind HIV-1 and to transmit infectious virus to T cells
[9]. The virus then actively replicates in activated CD4 T cells,
which are chronically induced during HIV infection by various
mechanisms [10,11].
During progression to AIDS, HIV(+) individuals become
increasingly immunosuppressed and susceptible to opportunistic
infections and some cancers. This is accompanied by progressive
depletion of DC from different anatomical compartments, but the
reasons for this remain largely unknown. For example, it has been
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demonstrated that by in situ hybridization, DC-SIGN expression
was significantly reduced in the spleen of SIV-induced AIDS [12].
Furthermore, in late-stage HIV infection, a dramatic depletion of
lymph node myeloid DC (mDC) was also observed, with mDC 20-
fold less frequent in HIV(+) nodes than in control nodes [13].
Consistently, another report employed flow cytometry and
immunofluorescence study to show that the frequencies of lymph
node mDC were significantly decreased in a model of simian
AIDS [14], suggesting that mDC are lost from rather than being
recruited to lymphoid tissue in advanced SIV infection. In
addition, mDC from SIV-infected animals undergo spontaneous
cell death during culture [14], supporting the hypothesis that the
loss of mDC may be due to cell death. Moreover, DC that are
annexin V-positive could be identified in the lymph nodes of
monkeys with AIDS, indicating that the DC in the LN may be
undergoing apoptosis [14].
Under normal circumstances the life-span and availability of
DC in vivo is crucial for the induction and maintenance of effective
antigen-specific T cell immunity [15,16]. For example, the
magnitude and quality of the CD4 T cell response is proportional
to the number of antigen-bearing DC that reach the lymph nodes
[17]. Normally, migration of DC from peripheral non-lymphoid
sites into secondary lymphoid tissues is promoted by DC
maturation, the process by which the cells acquire enhanced
capacities for T cell activation and the regulation of immune
responses. In peripheral sites of infection and inflammation, DC
maturation can be induced by stimuli such as bacterial lipopoly-
saccharide (LPS) and the pro-inflammatory cytokines TNF-a and
IL-b. Within the lymphoid tissues, further DC activation can be
induced by activated T cells that upregulate CD40 ligand (CD40L)
which ligates CD40 on the DC [18]. DC then undergo apoptosis
in a tightly-regulated process. Accumulating evidences have
demonstrated that the balance between survival versus apoptosis
of DC is controlled by differential expression of anti- and pro-
apoptotic molecules that are induced during different cellular
responses. For example, the above maturation stimuli can activate
phosphatydylinositide 3-kinase (PI3K) which phosphorylates Akt
(p-Akt) [19] and this, in turn, increases expression of anti-apoptotic
proteins such as Bcl-2 and Bcl-xL [20,21]. It has been further
shown that binding of HIV-1 gp120 to DC-SIGN recruits effector
proteins to the DC-SIGN signalosome to phosphorylate and
activate Raf-1 (p-Raf) [22]. Raf-1 is anti-apoptotic and can in turn
antagonize the function of another MAPKKK, apoptosis signal
regulating kinase-1 (ASK-1) [23]. ASK-1 can also be activated (p-
ASK-1) by the above stimuli but is pro-apoptotic, at least in part
through its capacity to reduce expression of Bcl-2 and Bcl-xL [24–
26]. Because the regulation of DC survival in peripheral and
lymphoid tissues is crucial for the initiation and regulation of
immune responses [15], any reduction in DC numbers would
result in generalised immunosuppression and increased suscepti-
bility to opportunistic and other infections, as is observed during
disease progression to AIDS.
We previously reported that chemotaxis of monocyte-derived
DC (moDC) can be induced by M-tropic HIV-1 (R5 strains)
through binding of gp120 to CCR5 [27]. This finding may in part
explain the observation that during acute HIV-1 infection there is
rapid accumulation of DC-SIGN(+) cells within the lymphoid
tissues [12]. In contrast, as disease progresses chronically to AIDS,
circulating and lymphoid tissue-associated DC become progres-
sively depleted [28–33]. These include DC-SIGN(+) DC which are
markedly reduced in lymph nodes of AIDS patients [34] and in
spleens of non-human primates with SIV-induced AIDS [12].
Clinical observations indicate that the increase in serum HIV-1
viral loads correlates well with the decrease in numbers of DC in
HIV-1-infected individuals [29,34–37], suggesting that the virus
itself or viral products such as shed gp120 may directly impact on
DC survival.
Much work has focussed on the mechanisms of immune
subversion by infectious HIV-1 virions, but relatively scant
attention has been paid to potential immunomodulatory effects
of the vast amounts of gp120 immune complexes within the
circulation of HIV(+) individuals. We hypothesised that binding of
gp120 to DC-SIGN(+)DC may have an impact on their survival,
thus contributing to the cellular depletion observed in the settings
above. Here we show that DC which are exposed to HIV-1 gp120,
either in vitro or in vivo, undergo accelerated apoptosis when they
are exposed to multiple stimuli that normally induce DC
maturation. Crucially, we also demonstrate that binding of
gp120 to DC-SIGN results in excessive activation of p-ASK-1,
and that silencing of ASK-1 effectively reverses this process and
promotes DC survival.
Results
Cross-linked gp120 sensitizes cultured DC to undergo
CD40L- and DC-SIGN-dependent apoptosis
We first studied the survival of gp120-pulsed DC that were
exposed to activated CD4 T cells, mimicking the interactions that
typically occur within secondary lymphoid tissues. Monocyte-
derived DC (moDC) were treated with antibody cross-linked
recombinant gp120 (gp120-DC) and co-cultured for 3 d with
activated or naı¨ve CD4 T cells. The gp120-DC were readily
identifiable within these co-cultures as a distinct, large granular
CD3(2)/DC-SIGN(+) cell population (Fig. S1). Analysis of
Annexin-V (AV) and propidium iodide (PI) expression in this
population revealed that a very high proportion of the gp120-DC
underwent apoptosis following co-culture with activated, but not
naı¨ve, CD4 T cells (Fig. 1A, right upper vs lower panel). Treatment
of moDC with cross-linked gp120 clearly induced apoptosis in
both a dose-dependent (Fig. 1B) and time-dependent (Fig. 1C)
Author Summary
HIV-1 infected individuals become increasingly immuno-
compromised and susceptible to opportunistic infection
during disease progression, which is associated with
significant reduction of the dendritic cell number in the
peripheral blood or secondary lymphoid tissues. Because
dendritic cells are the most powerful antigen-presenting
cells, their survival is critical for host defence and
inadequate dendritic cell number will fail to induce
effective host immune responses. Here we describe a
mechanism that may at least partly explain why dendritic
cells become significantly depleted in chronic HIV-1
infection. We found that after binding of the HIV-1
envelope protein gp120 to the dendritic cell surface
protein DC-SIGN, the subsequent activation by CD40
ligation, or by exposure to bacterial product lipopolysac-
charide or pro-inflammatory cytokines such as TNF-a and
IL-1b, will lead to overexpression of pro-apoptotic mole-
cule ASK-1, resulting in excessive dendritic cell death. We
also confirmed that DC-SIGN(+) dendritic cells in the blood
of HIV-1 infected individuals have actually been pre-
sensitized by viral gp120, which exists in vast amount in
the blood, for activation-induced exorbitant death. Our
study thus reveals a previously unknown pathway for
dendritic cell depletion and provides clues for potential
therapeutic approaches to prevent DC depletion in chronic
HIV infection.
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Figure 1. Cross-linked recombinant gp120 sensitizes moDC for CD40L-mediated apoptosis after co-culture with activated CD4 T
cells. (A) moDC were treated for 24 h with anti-His mAb alone (control DC, left panels) or with 25 nM gp120ADA cross-linked with anti-His mAb
(gp120-DC, right panels), and co-cultured with autologous activated (upper panels) or naı¨ve (lower panels) CD4 T cells for 3 d. The moDC (Fig. S1)
were analyzed for Annexin V (AV) and propidium iodide (PI) expression to assess the extent of apoptosis, as manifested by the percentage of the AV-
positive [AV(+)] cells. Data are representative of 5 experiments. (B) Apoptosis of moDC was analyzed after treatment with different concentrations of
cross-linked recombinant gp120ADA or gp120HXBc2 and co-culture with activated CD4 T cells for 3 d. DC treated with monomeric gp120 (not cross-
linked with anti-His or anti-FLAG mAb) were used as a control. Data represent mean 6 SD from 5 experiments; **p,0.01. The use of cross-linked
recombinant gp120BAL gave similar results (not shown). (C) Apoptosis of moDC was analyzed after treatment with the indicated cross-linked
recombinant gp120, or appropriate mAb controls, at the indicated time points after co-culture with activated CD4 T cells. Data represent mean 6 SD
from 5 experiments (data for anti-His and anti-FLAG controls were indistinguishable); *P,0.05 and **P,0.01 compared with control group (DC with
no gp120 pulse or DC plus anti-His/FLAG Ab). (D) moDC were respectively not treated (Control DC), or treated with gp120ADA cross-linked with
mouse IgG2a anti-His mAb (dimeric gp120-DC), or treated with cross-linked gp120ADA supplemented with isotype control mouse IgG (gp120-
DC+isotype IgG), and subsequently co-cultured with autologous activated CD4 T cells for 3 days before AV/PI staining. Data are representative of 3
experiments. (E) moDC were treated with cross-linked gp120ADA and co-cultured for 3 d with autologous activated or naı¨ve CD4 T cells, that had
been pre-treated without or with 10 mg/ml isotype control or anti-CD40L mAb, before cell viability analysis. Data are expressed as mean 6 SD from 5
experiments. **p,0.01.
doi:10.1371/journal.ppat.1003100.g001
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manner. In our preliminary time-chase experiments, we followed
AV/PI reactivity till d4 and found that the AV reactivity of DC
reduced from d3 to d4, whereas that of PI increased over time,
indicating that as incubation time increases, some cells at early
apoptotic (AV+PI2) phase would become late apoptotic (AV+PI+)
cells. Nevertheless, the overall AV(+) cells (ie, AV+PI2 plus
AV+PI+ cells) remained relatively consistent between d3 and d4
(Figure S1). We therefore chose d3 as our observation time point
to compare the % of total AV(+) cells among various treatment
conditions. Furthermore, while the cross-linked gp120 prompted
DC for activated CD4 T cell-mediated apoptosis, treatment with
monomeric gp120 did not (Fig. 1D). The formation of dimeric
gp120 after cross-linking with anti-‘‘tag’’ (anti-His or anti-FLAG
Ab) has been confirmed by native non-reducing Western blot
analysis (Fig. S2).
During the cross-talk between DC and activated CD4 T cells,
CD40-CD40L interactions play crucial roles in both the regulation
of DC survival and immune responses. To examine the potential
involvement of CD40/CD40L interactions in the induction of
apoptosis of gp120-DC, activated CD4 T cells were pre-treated
with an antagonistic anti-CD40L mAb before co-culture with
gp120-DC. Pre-treatment significantly inhibited the apoptosis of
gp120-DC (Fig. 1E). Therefore, activated CD4 T cell-mediated
apoptosis of immune-complex gp120-primed DC is at least in part
CD40L-dependent.
HIV-1 gp120 binding to DC-SIGN sensitizes moDC for
apoptosis
As DC-SIGN is one of the major surface molecules for gp120
binding on moDC, we examined the role of DC-SIGN in the CD4
T cell-induced DC apoptosis by pre-treating DC with anti-DC-
SIGN mAbs (a mixture of clones 120612 and DC28). The
combination of anti-DC-SIGN mAbs used for these studies
substantially reduced the binding of gp120 to DC-SIGN and
inhibited HIV-1 uptake (Fig. S3) by the DC-SIGN-transfectants.
Indeed, DC-SIGN blockade could significantly prevent DC
apoptosis upon coculture with activated CD4 T cells (Fig. 2A &
B). Because apoptosis of gp120-primed DC can be CD40L-
dependent, we studied if exposure of gp120-DC to CD40L-
transfected L (CD40L Tf) would lead to the same outcome. We
analysed AV/PI expression of moDC (which expressed HLA-DR,
Fig. S4) after separation from the adherent CD40L transfectants
(which expressed high levels of CD40L and little HLA-DR, Fig.
S4). We found that exposure to CD40L Tf cells also induced
significant apoptosis of gp120-DC, compared with exposure to
mock L cell transfectants (Fig. 2C, top panels, and Fig. 2D), and
cell death was further confirmed by trypan blue staining; Fig. S5).
We next tried to delineate the role of other gp120-binding
receptors (apart from DC-SIGN) of moDC that might also be
responsible for CD40L-induced apoptosis. We first pre-treated
moDC with anti-CD4/chemokine receptor and anti-DC-SIGN
mAbs, as previously described [38], and pulsed DC with cross-
linked recombinant gp120 for coculture with CD40L Tf cells for 3
days. Results showed that in contrast to DC-SIGN blockade, pre-
treatment with a combination of anti-CD4/chemokine receptor
mAbs did not inhibit moDC apoptosis (Fig. 2C–D). Pre-treatment
of moDC with cross-linked ICAM-3, a physiological ligand for
DC-SIGN (Fig. S6) that does not prevent gp120 binding, was also
ineffective in preventing apoptosis (Fig. 2C–D). Control studies
demonstrated that pre-treatment with these antagonistic mAbs
alone did not sensitize moDC for CD40-mediated cell death (Fig.
S6). Taken together, we conclude that cross-linking of DC-SIGN,
but not CD4/chemokine receptors, by recombinant gp120
sensitizes DC for apoptosis after CD40 ligation.
As HIV-1 gp120 binding to moDC has been shown to be
exclusively carbohydrate-dependent [39], we also examined the
role of carbohydrates of gp120 and if other mannose C-type lectin
receptor (MCLRs), in addition to DC-SIGN, could also be
involved in gp120/CD40L-mediated death. We adopted two
approaches: removing the carbohydrate moieties of recombinant
gp120 by EndoH (endo-b-N-glucosaminidase) before cross-linking
with anti-‘‘tag’’ Abs, and pretreating DC with mannan to compete
off the gp120 binding. Because DC express abundant FcR [40]
and FcR cross-linking may induce apoptosis of certain cells
[41,42,43], we also investigated the effect of FcR blockade prior to
gp120 pulsing. After EndoH treatment, the deglycosylated
monomeric gp120 had reduced molecular weight (<80 kDa,
reduced from <120 kDa), and after cross-linking in dimeric form,
they indeed lost their binding capacity to moDC (Fig. S2).
Furthermore, the immune-complex EndoH-treated gp120 lost the
ability in sensitizing DC for apoptosis upon CD40 ligation (Fig. 2E,
upper row, and Fig. 2F). Pre-treatment of moDC with mannan
prior to gp120 pulsing also completely prevented the CD40L-
mediated apoptosis, which was more potent than mere DC-SIGN
blockade. Moreover, while FcR blockade itself did not induce
CD40L-mediated apoptosis of control DC (pulsed with anti-‘‘tag’’
Ab), it significantly promoted further the extent of CD40L-
mediated apoptosis of gp120-DC (Fig. 2E, lower row, and Fig. 2F).
Immune complexes of gp120 from the sera of HIV-
positive individuals can sensitise cultured dendritic cells
for apoptosis
To investigate whether sera from HIV-1-positive (+) individuals
can contain sufficient levels of gp120 immune complexes to
sensitize moDC for CD40L-mediated apoptosis, we next treated
moDC with HIV-1(+) sera containing high viral copy numbers
(.400,000/ml) (Table S1). In order to eliminate the effect of other
soluble immune factors, the sera were first centrifuged through
filters with a cut-off point of 100 kDa and the .100 kDa fractions
were collected and reconstituted to the original volume with fresh
medium before use, as described [27]. After 3 d co-culture with
autologous activated CD4 T cells, the HIV-1(+) sera-treated
moDC were identified as a smaller-sized population than the
control moDC, and they were CD3(2) (Fig. S7). These cells were
then subjected to TUNEL assays with flow cytometric analysis to
evaluate terminal deoxynucleotidyl transferase (TdT) expression as
a measure of apoptosis. This confirmed that HIV(+) serum-pulsed
moDC had undergone remarkable apoptosis (,50%, Fig. 3A), and
that this could be substantially inhibited by pre-treatment with
anti-DC-SIGN mAbs (Fig. 3A–B) or anti-CD40L mAbs (Fig. 3B).
Furthermore, excessive apoptosis of moDC was effectively
prevented after removal of gp120 from the HIV-1(+) sera by
immunoprecipitation (IP) (Fig. 3A–B), under conditions that also
depleted virions from cultures of live virus (Fig. S8). Similar results
were obtained following co-culture of HIV-1(+) serum-treated
moDC with CD40L Tf cells, and further confirmed that CD4 and
chemokine receptors were not involved in sensitization for
apoptosis (Fig. 3C–D). Therefore, HIV-1(+) sera may contain
sufficient levels of immune complexed and/or virion-bound gp120
to sensitize moDC for CD40/CD40L-mediated apoptosis.
We next investigated the relative contributions of circulating
gp120 and virions from HIV(+) serum in sensitizing DC for
apoptosis. First, we treated moDC with .100 kDa fractions of
sera containing either relatively low (,100,000/ml) or high
(.400,000/ml) viral copy numbers (Table S1). After co-culture
with CD40L Tf cells, the extent of DC apoptosis was significantly
higher in treatment with serum of relatively high HIV RNA viral
loads (Fig. 4A). We next further fractionated the .100 kDa serum
HIV gp120 Sensitizes DC for Excessive Apoptosis
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fractions into virion-free (100–1000 kDa) and virion-enriched
(.1000 kDa) portions. The moDC were then treated with these
respective fractions and co-cultured with CD40L Tf cells. We
detected slightly higher levels of apoptosis after treatment with the
virion-enriched portions than controls, but substantial levels of
apoptosis was observed after treatment with the virion-free (gp120-
enriched) portion (Fig. 4B–C). Hence gp120, circulating as
immune complexes in HIV(+) sera, plays a more significant role
than virus-bound gp120 in sensitizing DC for CD40/CD40L-
dependent apoptosis.
In separate experiments, we also examined the sensitizing
capacity of EndoH-treated gp120, pre-treatment with mannan, as
Figure 2. Cross-linked gp120 sensitizes DC through DC-SIGN and MCLRs for CD40L-mediated apoptosis. (A, B) moDC were pretreated
with anti-DC-SIGN mAbs or isotype control Ab before pulse with cross-linked gp120ADA and co-culture for 3 d with autologous activated CD4 T cells,
and subsequently subjected to cell viability assay. Data are representative of 3 experiments and are expressed as mean6 SD from 3 experiments in B.
(C, D) moDC were treated with cross-linked recombinant gp120ADA with or without pre-treatment by soluble ICAM-3-Fc chimeric protein, anti-CD4
plus anti-CCR5 mAbs, or anti-DC-SIGN mAbs. Cells were subsequently co-cultured with mock- or CD40L-transfected (CD40L Tf) cells for 3 d. Data are
representative of 7 experiments in panel C and are expressed as mean6 SD (n = 7) in D; ***p,0.005. (E, F) Recombinant gp120ADA were treated with
or without EndoH, and then cross-linked with anti-His Ab before use to pulse moDC. Prior to gp120 pulsing, moDC were pre-treated with or without
mannan or FcR blocking reagent, or anti-DC-SIGN mAbs for 30 minutes. After gp120 pulsing, DC were subsequently cocultured with CD40 Tf for 3
days. DC without any pre-treatment and only pulsed with anti-His Ab were used as a control (control DC). Data are representative of 3 experiments
and expressed as mean 6 SD from 3 experiments in F; *p,0.05, **p,0.01.
doi:10.1371/journal.ppat.1003100.g002
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well as FcR blockade of DC for CD40L-mediated apoptosis.
Consistently as in the case of recombinant gp120 (Fig. 2E & F),
EndoH-treated HIV(+) serum had lost the capacity in priming DC
for CD40L-mediated apoptosis. Furthermore, compared with DC-
SIGN blockade, pre-treatment of DC with mannan (before pulse
by HIV(+) serum) further prevented DC apoptosis (down to
background levels). FcR blockade of DC prior to exposure to HIV
serum further increased the extent of DC death (Fig. S9).
Blood DC from healthy individuals can be sensitized for
apoptosis by gp120, and are pre-sensitized within the
circulation of HIV-1-positive individuals
To extend our studies beyond the use of in vitro-generated DC,
we next purified the DC-SIGN(+) subset of DC from peripheral
blood of normal individuals. Approximately 0.12–0.3% of
CD14(+) cells in blood expressed DC-SIGN (Fig. 5A; equivalent
to 0.01–0.03% of PBMCs), which also expressed CD40 and
CD11c (Fig. S10), consistent with a previous report [9]. After
priming by cross-linked gp120 and coculture with CD40L Tf cells,
these blood-derived DC also underwent excessive apoptosis, and
this was significantly reduced by prior blockade of DC-SIGN
(Fig. 5B). Hence this bona fide primary human blood DC subset can
be sensitized through gp120 ligation of DC-SIGN for CD40/
CD40L-dependent apoptosis.
Based on these and other findings above, we then hypothesized
that DC-SIGN(+) DC in the peripheral blood of HIV-1(+)
individuals would be excessively vulnerable to apoptosis due to
their continual exposure to high levels of immune-complex gp120
in the circulation. We therefore also isolated the DC-SIGN(+) DC
subset directly from the blood of HIV-1(+) individuals and found
that a substantial degree of apoptosis occurred after they were
cultured with CD40L Tf cells, whereas the same subset of DC
Figure 3. Sera from HIV-1(+) individuals can sensitize moDC for DC-SIGN dependent CD40L-mediated apoptosis. (A) moDC were
treated with HIV(+) serum before or after immunoprecipitation (IP) with anti-gp120 mAbs, or with or without anti-DC-SIGN or isotype control mAbs,
and subsequently co-cultured with autologous activated CD4 T cells. After 3 d, cells were harvested and subjected to TUNEL assays. Cell death was
assessed as the percentage of cells expressing terminal deoxynucleotidyl transferase (TdT). DC pulsed with HIV(+) serum without coculture with
activated CD4 T cells (top panel) were also used as a control. Data are representative of 4 experiments. (B) MoDCs were treated with anti-DC-SIGN
mAbs, isotype control Ab, or anti-CD40L mAb before pulse with HIV serum (before or after immunoprecipitation of gp120) and cocultured with
activated CD4 T cells. Data are expressed as mean6 SD (n = 4); *p,0.05 and **p,0.01 compared with ‘HIV(+) serum-DC plus isotype Ab’. (C,D) moDC
were treated with normal AB serum or HIV-1(+) serum with viral RNA copies .400,000/ml (Table S1), with or without pre-treatment with anti-CD4
plus chemokine receptor or anti-DC-SIGN mAbs, or with gp120-depleted (immunoprecipitated, IP) HIV(+) serum, and co-cultured with CD40L Tf for
3 d. Data are representative of 4 experiments in panel C and individual datum with the mean is shown in panel D; {: P,0.001 between with and
without IP of gp120 from the HIV serum, **: P,0.01 between with and without pre-treatment with anti-DC-SIGN mAbs.
doi:10.1371/journal.ppat.1003100.g003
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from HIV(2) individuals did not (Fig. 5C–D). We thus conclude
that DC-SIGN(+) DC from healthy human blood can be sensitized
for apoptosis after in vitro exposure to cross-linked gp120, and DC-
SIGN(+) in the circulation of HIV(+) individuals may have been
pre-sensitised in vivo by circulating immune complexes of gp120.
HIV-1 gp120 sensitizes cultured DC and blood DC for
apoptosis after exposure to LPS, TNF-a and IL-1b
We next studied the survival of gp120-primed DC after
exposure to typical stimuli that might be encountered at peripheral
sites of infection and inflammation, prior to DC migration to
lymphoid tissues. MoDC were treated with cross-linked recombi-
nant gp120 and subsequently cultured with 100 ng/ml LPS, TNF-
a or IL-1b for 3 d. Very considerable levels of apoptosis were
induced in gp120-primed DC after exposure to LPS, and this
could be significantly prevented by prior blockade of DC-SIGN
(Fig. 6A–B). Likewise, substantial levels of apoptosis were also
induced after exposure to TNF-a and IL-1b (Fig. 6C). Excessive
apoptosis was further induced when the cross-linked gp120 was
replaced by HIV-1(+) sera containing high viral loads (.400,000
RNA copies/ml) prior to LPS stimulation, but was prevented by
prior immunoprecipitation of gp120 from the sera and substan-
tially reduced by blockade of DC-SIGN, but not CD4/CCR5
(Fig. 6D).
To extrapolate our findings to the in vivo setting, DC-SIGN(+)
cells from the peripheral blood of HIV-1(+) or HIV-1(2)
individuals were isolated and exposed to 100 ng/ml LPS, TNFa
or IL-1b. While there was little apoptosis of blood DC from
HIV(2) individuals, blood DC-SIGN(+) DC from HIV(+)
individuals underwent substantial apoptosis, indicating that they
are pre-sensitized in vivo to die after contact with multiple stimuli
that otherwise induce DC maturation (Fig. 6E–F).
Figure 4. CD40L-mediated apoptosis of HIV(+) serum-pulsed DC is proportional to viral loads and predominantly induced by the
100–1000 kDa fraction. (A) moDC were treated with HIV-1(+) sera with viral copy numbers .400,000/ml or ,100,000/ml or normal AB serum
(control) and co-cultured with CD40L Tf cells for 3 d. Data are expressed as individual datum with the mean. N = 4 for each condition; *p,0.05 and
**p,0.01. (B, C) moDC were treated for 24 h with normal AB serum or with .1000 kDa or 100–1000 kDa fractions from HIV(+) serum and were co-
cultured with CD40L Tf for 3 d. Data are representative of 5 experiments in B and expressed as mean 6 SD in C; ** p,0.01.
doi:10.1371/journal.ppat.1003100.g004
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Binding of HIV-1 gp120 to DC-SIGN promotes ASK-1-
dependent apoptosis of human dendritic cells
To explore potential mechanisms by which gp120 ligation of DC-
SIGN sensitizes DC for apoptosis, we first noted that treatment of
moDC with cross-linked gp120 alone was able to modulate the
expression of key membrane molecules in a manner that is typically
associated with DC maturation (Fig. S11), as reported by others
[44]. Together with our earlier observations (Fig. 1C; cf. apoptosis of
gp120 at d2 vs. control DC at d4), this finding suggested that gp120
ligation of DC-SIGN greatly accelerates an apoptotic programme
that is normally induced following maturation.
We then studied components of the intracellular signalling
pathways that might be involved in gp120 sensitization of DC for
apoptosis. MoDC were treated with cross-linked gp120, or with
HIV(+) sera, and co-cultured with CD40L Tf cells or exposed to
LPS, TNFa or IL1b (as above). After 3 days, moDC were harvested
from the cultures and Western blot assays were performed to
analyze the expression of key molecules regulating the balance of
DC survival versus death. First, we noted a substantial reduction in
the expression levels of the anti-apoptotic molecules Bcl-2 (Fig. 7A),
and Bcl-xL (Fig. S12), after exposure of cross-linked gp120-DC
(Fig. 7A) or HIV(+) sera-treated moDC (Fig. S12) to the above
stimuli. Second, turning to upstream components that may lead to
these changes we found that p-Raf-1, which can be activated by the
DC-SIGN signalosome after gp120 binding, was increased as
expected but little further change occurred after exposure to the
various stimuli. In marked contrast, each of these stimuli resulted in
a marked reduction of p-Akt which is anti-apoptotic, but a very
substantial increase in p-ASK1 which is pro-apoptotic. Studying the
latter in more detail, we found the expression of p-ASK1 could be
reduced virtually to baseline levels (moDC with stimuli alone) by
DC-SIGN blockade (Fig. 7A, lower three panels).
The above observation indicates that gp120 ligation of DC-
SIGN, either directly or indirectly, leads to excessive ASK1
activation which promotes DC apoptosis. To confirm the role of
ASK1, we transfected moDC with ASK1-specific siRNA before
treatment with gp120 and exposure to different activation stimuli.
In all cases, silencing of ASK1 substantially prevented excessive
DC apoptosis in response to each of the activation factors (Fig. 7B).
Therefore, gp120 ligation of DC-SIGN accelerates an apoptotic
programme that normally accompanies DC maturation, and
which involves excessive ASK-1 activation that results in unusually
premature cell death.
Discussion
In chronically-infected HIV-1(+) individuals, multiple subsets of
DC in peripheral blood [29–31,36] and lymphoid tissues [12,34]
Figure 5. Freshly-isolated DC-SIGN(+) blood DC underwent DC-SIGN-dependent CD40L-mediated apoptosis and DC-SIGN(+) cells
from HIV-1-infected individuals are pre-sensitized for CD40L-mediated apoptosis. (A) PBMCs from normal HIV(2) individuals were
labelled with anti-CD14 plus either isotype control (left panel) or anti-DC-SIGN (right panel) mAbs and analysed by flow cytometry for cell isolation.
Data are representative of 4 experiments. (B) Purified CD14(+)DC-SIGN(+) cells were treated with anti-His mAb alone (Control) or anti-His cross-linked
recombinant gp120ADA, in the absence or presence of anti-DC-SIGN mAbs, and subsequently co-cultured with CD40L Tf for 3 d. The non-adherent DC
were then harvested and subjected to cell viability assay. Data are representative of 4 experiments. (C, D) freshly isolated DC-SIGN(+) cells from HIV(+)
and HIV(2) blood were cocultured with mock Tf or CD40L Tf for 3 days and subjected to cell viability assay. Data are representative of 4 experiments
in C and expressed as mean 6 SD in D. ***p,0.005.
doi:10.1371/journal.ppat.1003100.g005
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become progressively depleted during disease progression to
AIDS, and the reduction of DC number is proportional to the
viral RNA loads [29,35,37]. It is unlikely that direct infection and
killing of DC by HIV-1 can account for this substantial depletion,
given the remarkably low frequency of cells that are actually
infected. We present in this study a gp120-exerted mechanism that
Figure 6. Cross-linked recombinant gp120 or HIV(+) serum sensitizes moDC for apoptosis after activation by LPS, TNF-a or IL-1b,
and DC-SIGN(+) cells in HIV(+) blood are pre-sensitized for LPS/TNFa/IL-1b-induced apoptosis. (A,B) moDC were treated with gp120ADA
in the presence of isotype control or anti-DC-SIGN Abs and subsequently cultured in the absence or presence of 100 ng/ml LPS for 3 d. Data are
representative of 5 experiments in A and are expressed as mean 6 SD in B; **p,0.01, ***P,0.005. Similar findings were made after treatment with
gp120BAL or gp120HXBc2 (not shown). (C) moDC were treated with anti-His cross-linked recombinant gp120ADA (gp120-DC) or anti-His Ab alone
(Control DC), and cultured for 3 d in the absence (no activation) or presence of 100 ng/ml LPS, TNF-a or IL-1b. Data represent mean 6 SD from 4
experiments; **p,0.01 and ***p,0.005. (D) moDC were treated with normal AB serum or HIV-1(+) sera (viral RNA copies .400,000/ml; n = 4) before
or after gp120 immunoprecipitation (IP), with or without pre-pretreatment with anti-CD4 plus anti-CCR5, or anti-DC-SIGN mAbs and subsequently
exposed to 100 ng/ml LPS for 3 d; **P,0.01 and {P,0.001. (E,F) DC-SIGN(+) cells from HIV(+) and HIV(2) blood were cultured in the absence (‘No
stimuli’) or presence of 100 ng/ml of LPS, TNFa, or IL-1b for 3 d prior to analysis of cell viability. Data are representative of 4 experiments in E and
expressed as mean 6 SD (n = 4) in F. {P,0.001 between cells from HIV(+) blood and from HIV(2) blood.
doi:10.1371/journal.ppat.1003100.g006
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may account, at least in part, for the progressive depletion of
conventional DC subsets, as seen in chronic HIV infection. We
provide evidence that moDC can be sensitized by cross-linked
recombinant gp120 (Fig. 1 and 2), and HIV-1(+) sera (Fig. 3 and
4), to undergo greatly accelerated apoptosis in response to CD40
ligation, which typically occurs after DC migration into lymphoid
tissue. The extent of DC apoptosis was proportional to the
concentration of recombinant gp120 (Fig. 1B) and viral RNA
loads in the sera (Fig. 4A). These observations were reinforced by
the finding that CD14(+)DC-SIGN(+) DC, isolated directly from
the blood of healthy [HIV(2)] individuals, could also be sensitized
by gp120 for CD40L-induced cell death (Fig. 5). Immunoprecip-
itation of gp120 from HIV-1(+) sera substantially reduced the
extent of apoptosis, showing that either virion-bound gp120 and/
or gp120 in the circulating immune-complex form could sensitize
the cells (Fig. 3). When we further fractionated the HIV(+) sera, we
found that the 100–1000 kDa (virion-free) portion promoted
substantial levels of apoptosis after CD40 ligation, whereas
considerably lower levels were induced by the .1000 kDa
(virion-enriched) portion (Fig. 4B–C). Since the molecular weight
of IgG is ,150–170 kDa, circulating immune-complex gp120
would be contained in the virion-free fractions (100–1000 kDa).
Therefore, gp120 in immune complexes is primarily responsible
for sensitizing DC for apoptosis, and HIV(+) serum we tested
contains sufficient quantities of circulating gp120 in vivo to sensitize
DC-SIGN(+) DC for apoptosis. However, it remains to be studied
if the smaller amount of sensitization by the virion-rich fraction
might be induced by activities other than mere gp120/DC-SIGN
binding (e.g., events after viral entry). To evaluate our findings
further and more directly, we isolated CD14(+)DC-SIGN(+) DC
from the blood of HIV(+) individuals and found that they were
indeed ‘pre-sensitized’ for apoptosis on CD40 ligation (Fig. 5).
Moreover, both these blood DC from HIV(+) individuals and
moDC sensitized by recombinant or serum gp120 underwent
substantial apoptosis after exposure to bacterial LPS and the pro-
inflammatory cytokines TNF-a and IL-1b (Fig. 6), apart from
CD40 ligation.
Amongst HIV-1 encoded proteins, the envelope protein gp120
has two very unusual properties, even for a retroviral envelope
component: first, gp120 is only loosely attached to the virion and is
rapidly shed in large quantities into the circulation [3], and
second, liberated gp120 binds to and activates a very high
proportion of B cells [28,45], resulting in a massive overproduction
of anti-gp120 antibodies and the formation of increasing amounts
of immune complexes in the serum. Our findings now reveal that
through ligation of immune-complex gp120 to DC-SIGN and
mannose C-type lectin receptors (MCLRs), apoptosis of DC is
remarkably promoted when the cells encounter diverse maturation
stimuli that are otherwise prerequisites for the effective initiation
and regulation of many immune responses. The concentration of
‘‘free gp120’’ in the HIV(+) serum has been studied by many
groups, varying from ‘‘pM’’ to ‘‘nM’’ levels [3,4,46,47]. However,
most reports determining the free gp120 in HIV(+) serum
employed an antigen capture assay (eg, ELISA) without taking
into account the presence of anti-gp120 Ab in the serum, which
could significantly mask the detection of free gp120 and sometimes
completely abrogate the signals [4]. The levels of ‘‘free gp120’’
detected in previous reports, thus, may not represent those of
antibody-bound gp120. It has been demonstrated that anti-gp120
Abs are present in the HIV(+) serum at high enough concentra-
tions to bind most of gp120 [48] and the levels of anti-gp120 Abs
have been estimated to be in the micromolar range [49].
Therefore, for high affinity binding (Kd,10 nM between gp120
and anti-gp120 Ab), virtually all the gp120 in the HIV(+) serum
might have been occupied (saturated) by antibodies [48]. In a
recent report, it has been estimated that the gp120 levels could be
up to 5 mg/ml when concentrations of all forms (soluble and cell/
virion-bound) are added, in situations of high plasma viremia [47].
The concentration of the immune-complex gp120 we used in the
current study, therefore, is not incompatible with the in vivo
scenario. Furthermore, it is interesting to note that even in the
same experimental model, DC might have different reactivity over
AV or PI in the viability assay. Throughout the entire study,
around 50% of the donors had more exaggerated PI staining,
while the other had more prominent AV staining (for instance,
Fig. 5B vs 5C). It is likely that DC from different individuals may
have different responsiveness to activation signals such as CD40
ligation, a phenomenon of ‘‘donor-to-donor variation’’, which has
Figure 7. Activation of gp120-primed DC reduced the expression of Bcl2 and activated Akt, and the induction of cell apoptosis is
ASK1-dependent. (A) moDC treated with immune-complex gp120ADA were exposed to CL40L Tf or mock Tf, or LPS, TNFa, IL-1b for 3 d, and cellular
proteins of moDC (recovered from coculture) were extracted for Western blotting analysis. MoDC treated by anti-His Ab (used to cross-link
recombinant gp120ADA) were used as a control (control DC). *p-ASK1 represent results from untreated moDC (lane 1) and DC treated as indicated but
no gp120 pulsing (lanes 2–6), whereas #p-ASK-1 represents results from pre-treatment of anti-DC-SIGN mAbs. Data are representative of 3
experiments. (B) moDC were transfected with siRNA against human ASK1 or control siRNA (scrambled) before pulse with immune-complex gp120
and subsequent exposure to CD40L Tf, LPS, TNFa or IL-1b. Data are expressed as mean 6 SD from 3 experiments. **p,0.01.
doi:10.1371/journal.ppat.1003100.g007
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been recently reported for HIV gp120 binding to moDC to induce
IL-10 and impair IL-12 production [24]. Differential responsive-
ness to CD40 ligation in DC has also been reported that in mouse
DC which express CD40high could produce more IL-12 but less
IL-10 than those produced by the CD40low DC [50]. It deserves
further investigation to see if the expression levels of CD40 of
moDC correlate with the degree of CD40L-mediated apoptosis,
and if DC apoptosis may also be accompanied by IL-10
production [24].
In studies to identify the membrane receptor(s) on DC through
which cross-linked gp120 and HIV(+) sera can sensitize the cells,
we observed that apoptosis was considerably reduced after pre-
treatment with antagonistic mAbs specific for DC-SIGN, but not a
combination of CD4 and chemokine receptors CCR5 or CXCR4
(Fig. 2A–D, Fig. 3C–D, 5B and 6D). In contrast, pre-treatment of
DC with a cross-linked, Fc construct of ICAM-3, a physiological
ligand for DC-SIGN important for stabilizing the DC-naı¨ve T cell
immune synapse [51], was ineffective (Fig. 2C–D). This is in
accordance with previous reports that the binding site for ICAM-3
is distinct from that of gp120 [52], and that soluble ICAM-3 is not
able to compete efficiently with HIV-1 envelope protein or with
intact viruses for binding to DC-SIGN [53]. Notably, the
inhibition of apoptosis by DC-SIGN blockade was substantial
but incomplete, apparently reflecting the relative capacity of the
combination of mAbs to prevent binding of gp120 to DC-SIGN
(Fig. S3). Furthermore, other MCLRs in addition to DC-SIGN
that can bind gp120 [32] are also involved in DC apoptosis,
because pre-treatment of DC with mannan led to virtually
complete diminishment of the CD40L-mediated DC death, in
contrast to partial (albeit significant) inhibition by DC-SIGN
blockade (Fig. 2E–F). Moreover, we agree with a previous report
[39] and confirm that gp120 binding to moDC is exclusively
carbohydrate-dependent because the binding capacity of deglyco-
sylated gp120 (whose carbohydrate moieties were removed by
EndoH treatment) to moDC was completely lost (Fig. S2),
resulting in total abrogation of CD40L-mediated apoptosis of
gp120-DC (Fig. 2E & F). Similar effects were also demonstrated in
the use of HIV(+) serum (Fig. S9).
We also noted that sensitization of DC for apoptosis was only
achieved with cross-linked recombinant gp120, and presumably
gp120 immune complexes in HIV(+) sera, but not with gp120 in
monomeric form (Fig. 1E). This suggests that cross-linking of DC-
SIGN is required for sensitization. Indeed, antibody cross-linking
of DC-SIGN [54] and the binding of HIV-1 gp120 [8] or many
other pathogens [55–58] have been shown to initiate diverse
intracellular signalling pathways in DC that lead to different
cellular responses. Along with this thought, we blocked the Fc
receptor (FcR) of moDC (before pulse by immune-complex gp120
or HIV(+) serum) in order to allow more potent clusterization of
DC-SIGN or other MCLRs. This indeed resulted in more
abundant DC apoptosis (Fig. 2E–F & Fig. S9). This finding
further supports the involvement of DC-SIGN or MCLRs in
gp120 sensitization for CD40L-induced DC death. Another point
to support DC-SIGN for gp120-triggered intracellular signalling is
that, apart from sensitizing DC for accelerated activation-induced
death, gp120 can also induce phenotypic changes of DC that are
typical of maturation (Fig. S11). The role of MCLRs in gp120-
mediated DC phenotypic maturation has also been reported by
others [44]. Therefore, immune-complex gp120 binding to DC-
SIGN (or other MLCRs) may have sensitized DC into a ‘‘pre-
mature’’ state, which may be a pre-requisite that prompted DC to
be more vulnerable to activation-induced apoptosis. However,
when compared with conventional maturation (e.g., LPS/TNFa/
IL-1b and CD40 ligation), the gp120-induced phenotypic
‘‘maturation’’ appeared inefficient, as manifested by less remark-
able upregulation of CD80, CD86, CD83 and CCR7. The CCR5
downregulation was also less noticeable than that induced by
conventional factors; in contrast, MHC class II upregulation
remained relatively unaffected (Fig. S11). Such inefficient matu-
ration is in line with a previous report that gp120 binding to
MCLRs can induce immunosuppressive responses from DC, such
as IL-10 production, which may subsequently contribute to a
weaker T cell stimulation capacity [24].
In exploring the mechanistic basis for the gp120 sensitization
process, we observed marked decrease in the downstream anti-
apoptotic components Bcl-2 (Fig. 7A) and Bcl-xL (Fig. S12).
Turning to upstream components that may account for these
observations and explain excessive apoptosis, we found that gp120
binding activated Raf-1, an anti-apoptotic through its activity to
restrict caspase activation [41], as reported by others [22], and its
expression was not significantly modulated upon exposure to
maturation stimuli (Fig. 7A). Strikingly, however, anti-apoptotic p-
Akt was markedly reduced whereas pro-apoptotic ASK-1 was very
substantially increased. Crucially, pre-treatment of gp120-DC with
anti-DC-SIGN mAbs reduced ASK-1 activation back to control
levels (Fig. 7A), while siRNA silencing of this component
substantially prevented DC apoptosis (Fig. 7B). Hence, gp120
binding to DC-SIGN activates ASK-1 and further exposure to the
different maturation stimuli results in abundant p-ASK-1 expres-
sion which may account for the excessive levels of apoptosis.
Whether or not this is directly due to activation of a novel ASK-1-
dependent signalling pathway after gp120 ligation of DC-SIGN,
or another pathway that releases inhibition by p-Akt, deserves
further attention. Furthermore, since HIV-1 Nef can suppress
ASK-1 activation in infected T cells to protect them from
apoptosis [49], it would be interesting to determine whether or not
infected DC can be protected in a similar manner while the
uninfected ‘bystander’ cells are killed.
Based on our findings, we propose that the capacity of gp120 to
ligate DC-SIGN and sensitize conventional DC for apoptosis after
encounter with diverse activation stimuli that otherwise induce
cellular maturation may account for the depletion of DC-SIGN(+)
DC, which has been clearly demonstrated in lymph nodes of
HIV(+) patients [12] and in spleens of SIV-infected non-human
primates [12]. We further propose that during disease progression
to AIDS, this may contribute to the decreased capacity to mount
effective immune responses [15–17,59] and also to increased
susceptibility to multiple opportunistic infections. In fact, the types
of infection that are seen during AIDS progression somewhat
resemble those described for some of the recently identified DC
deficiency syndromes [13]. The presence of LPS, resulting from,
for example, the mucosal barrier of the GALT being compromised
or concomitant bacterial infections [14,50], can also potentiate
HIV-induced immunosuppression through augmentation of HIV-
1 gene expression at least in part by stimulating the secretion of
TNF-a and IL-1b [60]; high levels of circulating TNF-a can also
be detected in HIV-infected individuals [61]. These factors could
well predispose ‘bystander’ DC-SIGN(+) cells, which have been
pre-sensitized by gp120 in the serum, for exorbitant apoptosis in
the lymphoid tissues or blood.
In a broader context, it is clear that many other pathogens may
also bind DC-SIGN to subvert DC functions, and DC-SIGN
ligation can modulate TLR-associated activation [55–58]. It
therefore deserves further study if such pathogens can also
decrease the survival of DC through their capacity to cross-link
DC-SIGN. Also, whether the subsequent modulation of TLR
responsiveness can additionally or synergistically contribute to the
defects of pathogen-specific immunity in AIDS warrants further
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investigation. In a narrower context, it is also clear that many
other mechanisms can contribute to depletion of different subsets
of DC during HIV-1 infection, including negative control of the
numbers of plasmacytoid DC by type I interferons [28]. Whether
or not binding of gp120 to other membrane receptors of DC can
sensitize the respective subsets for apoptosis also needs to be
further clarified. Finally, accelerated activation-induced apoptosis
of gp120-sensitized DC is accompanied by excessive activation of
ASK-1, and that silencing of ASK1 prevents apoptosis, implying
that antagonistic ASK1 therapies, such as have been shown to
reduce SIV encephalitis in macaques [48], might be of value to
prevent DC depletion during HIV-1 disease progression.
Materials and Methods
Preparation of monocyte-derived DC and treatment with
recombinant gp120 treatment (gp120-DC)
Monocyte-derived DC (moDC) were generated by culture for
6–7 d in RPMI1640 supplemented with 5% autologous serum,
GM-CSF and IL-4 as described [27]. The moDC were then
purified by two rounds of immunomagnetic depletion (Dynabeads,
Dynal, Oslo, Norway) using monoclonal antibodies (mAbs) against
CD3, CD8, CD14, CD16, CD19, and CD56 (BD PharMingen,
San Diego, CA, USA); the resultant HLA-DRhigh cell population
was .98% pure (data not shown). Recombinant His-tagged
gp120ADA, and FLAG-tagged gp120BAL and gp120HXBc2, were
prepared as described [27]; each contained ,5 EU/ml LPS by
Limulus amebocyte lysate (LAL) assay. 16105 moDC were
cultured in 6-well tissue culture plates (Corning Life Sciences
Corp., USA) at 37uC for 24 h in culture medium as described [27]
with 50 nM recombinant R5 (HIV-1ADA and HIV-1BAL), or X4
(HIV-1HXBc2) gp120. Before use, the gp120 was cross-linked by
incubating for 24 h at 37uC with respective anti-His (mouse IgG2a
isotype) or anti-FLAG (mouse IgG1 isotype) mAbs (Sigma–
Aldrich, USA) at a molar ratio 2:1 (gp120 vs anti-His or anti-
FLAG mAb), resulting final cross-linked gp120 of 25 nM.
Therefore, gp120 was used in an immune-complex rather than
monomeric form, unless otherwise stated. In experiments to
remove the carbohydrate moieties of gp120 by enzymatic
digestion, we pre-treated the monomeric recombinant gp120 with
endo-b-N-glucosaminidase H (EndoH; New England Biolabs,
Cambridge, Mass, USA) by incubating recombinant gp120
supernatant with 25 KU of EndoH/ml for 16–18 hours, as
described [39]. The extent of deglycosylation was then examined
and confirmed by SDS-PAGE and Western blot analysis using
polyclonal rabbit anti-gp120 antibodies (Fig. S2A). We then cross-
linked the EndoH-treated monomeric gp120 (which had poly-His
or FLAG at the COOH terminus) with anti-His or anti-FLAG Ab
to form immune-complex (dimeric) gp120, as described above.
The cross-linked EndoH-treated and -untreated gp120 were
further examined by Western blot analysis in native non-reducing
conditions, confirming the dimerization after addition of anti-His
or anti-FLAG Ab (Fig. S2B). The binding of Endo-treated and -
untreated dimeric gp120 to moDC was subsequently compared by
flow cytometry, demonstrating that EndoH-treated gp120 had lost
the binding to moDC (Fig. S2C).
Pre-treatment of DC with receptor antagonists, mannan,
and FcR blockade
To block gp120 binding to CD4 and chemokine receptors, DC
were pre-treated at 4uC for 1 h with 10 mg/ml each anti-CD4
(RPA-T4) plus either anti-CCR5 (clone 2D7; mouse IgG2a) or
anti-CXCR4 mAbs (clone 12G5, mouse IgG2a; all from BD
PharMingen, San Diego, CA, USA). To block DC-SIGN, DC
were similarly pre-treated with anti-DC-SIGN mAbs clone
120612 (mouse IgG2a; R & D Systems, MN, USA) plus DC28
(mouse IgG2a; AIDS Research and Reference Reagent Program,
NIH) in combination at 10 mg/ml each. This combination of anti-
DC-SIGN mAbs significantly inhibited both R5 and X4 gp120
binding to DC-SIGN-transfected 293 cells (Fig. S4A), and HIV-1
uptake into DC-SIGN-transfected THP-1 cells (a kind gift from Dr
V. KewalRamani, HIV Drug Resistance Program, National
Cancer Institute at Frederick, NIH, MD, USA; Fig. S4B). Soluble
polyhistidin(HIS)-tagged ICAM-3-Fc chimeric protein (R & D
Systems, Abingdon, UK; Fig. S4C), cross-linked with anti-His Ab
(as above), was also used to pre-treat DC at 10 mg/ml for 1 h
before use. After pre-treatment with receptor anatagonists, DC
were washed and treated with or without recombinant gp120 as
above or HIV(+) serum as below. In some experiments, we
examined the effects of mannan in competing off gp120 binding
and also the FcR blocking to enhance gp120 binding by pre-
incubating moDC with mannan (50 mg/ml, Sigma, USA) or 30 ml
FcR blocking reagent (Miltenyl Biotec, USA), or anti-DC-SIGN
mAbs (as described above) for 30 minutes before pulse by EndoH-
treated or –untreated gp120 pulsing with subsequent 3 days’
coculture with CD40 Tf.
Co-culture of gp120-DC with activated or naı¨ve T cells
Autologous naı¨ve CD4+ T cells were isolated from peripheral
blood mononuclear cells (PBMCs) after two rounds of immuno-
magnetic depletion (Dynabeads, Dynal, Oslo, Norway) using a
cocktail of mAbs against CD8, CD14, CD19, CD40, CD45RO,
CD56 and HLA-DR (BD PharMingen, San Diego, CA, USA).
The resultant cells were .98% CD4(+) CD45RA(+) (data not
shown). Activated CD4+ T cells were prepared by treating naı¨ve T
cells with 10 ng/ml PMA and 1 mg/ml ionomycin (Sigma, St
Louis, USA) for 24 h; they expressed high levels of CD40L (Fig.
S3, left panel) whereas expression was very low or undetectable on
naı¨ve CD4 T cells (data not shown). 16105 recombinant gp120-
primed moDC were co-cultured with 16105 activated or naı¨ve
CD4 T cells in 96-well plates for 3 d. Cells were then stained with
anti-CD3-cychrome, Annexin V-FITC and Propidium Iodide (all
from BD PharMingen, San Diego, USA). Apoptosis of DC was
determined by the Annexin V-FITC and Propidium Iodide
staining of the large granular cells in the FSC-SSC plot using a
FACSCalibur instrument (Becton Dickinson, San Diego, CA,
USA); these large granular cells were confirmed to lack expression
of CD3 but to express high levels of DC-SIGN (Fig. S1A–B). For
blocking CD40 ligand, activated CD4 T cells were treated with
10 mg/ml anti-CD40 ligand mAb (Alexis, Lausen, Switzerland) for
1 h at 4uC and washed before co-culture with gp120-DC.
Culture of gp120-DC with CD40L transfectants, LPS, TNFa
and IL-1b
16105 purified moDC were treated with cross-linked recombi-
nant gp120 for 24 h, with or without prior receptor blockade, and
co-cultured with 2.56104 CD40 ligand-transfected L (CD40L Tf)
cells (a kind gift of Dr Yong-Jun Liu, MD Anderson Cancer
Center, Texas, USA) in 96-well plates; the transfectants expressed
high levels of CD40L, similar to those of activated CD4 T cells
(Fig. S3, right panel). Before co-culture, the CD40L Tf cells were
treated with 50 mg/ml mitomycin C (Sigma, St Louis, MO, USA)
for 30 minutes at 37uC, in order to prevent cellular proliferation.
After 3 days coculture, the cells were stained with cychrome-
labeled anti-HLA-DR mAb (BD PharMingen, San Diego, USA),
Annexin V-FITC and propidium iodide. Essentially all the moDC
could be harvested by vigorous pipetting and re-suspension to
separate them from the firmly adherent CD40L Tf cells; .98% of
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recovered cells expressed high levels of HLA-DR, whereas
virtually no cells remaining in the wells expressed HLA-DR after
being detached with EDTA (Fig. S2A). The survival of gp120-DC
was determined by Annexin V and/or propidium iodide staining
of cells in the HLA-DR(+) gated population, and by trypan blue
staining (Fig. S2B). Co-culture of gp120-DC with mock transfected
L cells was used as a control. Apoptosis of DC was also examined
after culturing gp120-primed DC with 100 ng/ml each LPS
(Salmonella typhosa, Sigma, St Louis, USA), TNF-a or IL-1b
(Peprotech, NJ, USA) for 3 d.
Isolation of DC-SIGN(+) cells from peripheral blood of
HIV-uninfected [HIV(2)] and -infected [(HIV(+)]
individuals
DC-SIGN(+) cells were isolated from HIV-1(2) individuals as
described [9]. Briefly, 56108 PBMCs were collected from buffy
coats of healthy individuals and the T, B and NK cells were
removed by immunomagnetic depletion (Dynabeads, Dynal, Oslo,
Norway) with a cocktail of anti-CD3/CD20/CD56 mAbs (BD
PharMingen, San Diego, CA, USA). Cells were subsequently
stained with PE-conjugated anti-CD14 (BD PharMingen, CA,
USA) plus FITC-conjugated anti-DC-SIGN (AZN-D1, Beckman
Coulter, CA, USA) mAbs, and subjected to positive sorting using a
FACS Vantage (BD Bioscience, CA, USA); yields for DC-SIGN(+)
cells ranged from 5–156104 cells (i.e., 0.01–0.03% of the starting
PBMC population). Cells were then cultured for 2 h in the
presence of 5 mM EDTA to remove the bound mAb, washed, and
cultured in fresh medium for additional 1–2 h. 26104 DC-
SIGN(+) cells were then exposed to recombinant gp120ADA and
cocultured with CD40L transfectants before assessing cell viability
as above. DC-SIGN(+) cells were similarly isolated from 36108
PBMCs of HIV-1(+) individuals after ethical review (Table S1); the
yield ranged from 8–136103 cells (,0.0027–0.0043% of starting
PBMC). Cells were then treated and cocultured with CD40L Tf
cells, or exposed to 100 ng/ml LPS, TNFa or IL-1b, prior to
analysis [62] of cell viability as above.
Treatment of moDC with serum and filtrates from HIV-
1(+) individuals
The serum and PBMCs of HIV(2) individuals were obtained
from blood collected for a genotyping study [62]. The whole
HIV(+) serum was provided by the AIDS Research Laboratory,
Department of Microbiology, Queen Mary Hospital, The
University of Hong Kong, with approval of the Institutional
Review Board. Before use, HIV-1(+) sera (Table S1) were
centrifuged through ultra-centrifugal filters (Millipore, MA,
USA) with a cut-off point of 100 kDa and fractions .100 kDa
were reconstituted to the original volume with fresh medium as
previously described [27]. Immunoprecipitation (IP) with anti-
gp120 mAbs was performed as described [27] and resulted in over
80% reduction of the p24 level (Fig. S7). Where indicated, the
.100 kDa fraction was further fractionated by centrifugation
through ultra-centrifugal filters with a cut-off point of 1000 kDa
after which the ,1000 kDa and .1000 kDa portions were each
reconstituted to the original volume with fresh medium. 16105
moDC generated from PBMC of HIV(2) individuals were
exposed to the respective HIV(+) serum fractions (above) for
24 h at room temperature, washed, and then co-cultured with
CD40L Tf or autologous activated CD4 T cells, or 100 ng/ml
LPS, for 3 d. After recovery from the adherent CD40L Tf cells
(Fig. S2A), apoptosis of moDC was determined by Annexin V and
PI staining as above. Alternatively, for biosafety reasons after co-
culture with activated CD4 T cells, apoptosis was determined by
terminal deoxynucleotidyl transferase (TdT) dUTP nick end
labelling (TUNEL) assay using the In-Situ Cell Death Detection
Kit (Roche Diagnostics, Inc.), according to manufacturer’s
instructions; the recovered moDC were fixed, permeabilized and
subjected to TUNEL reaction mix incubation at 37uC for 1 h,
followed by cytometric analysis.
Western blotting and siRNA transfection
Purified moDC were pulsed with or without whole HIV-1(+)
sera or recombinant gp120ADA for 24 h, washed, and respectively
co-cultured with CD40L Tf cells or LPS, TNFa or IL-1b for 3 d,
as described before. MoDC could be separated from CD40L Tf
and recovered by pipetting and re-suspension in the co-culture
wells. In preliminary experiments, the recovered cells were
confirmed to express high MHC class II (HLA-DR), while the
CD40L Tf (which could be subsequently detached by treatment
with 5 mM EDTA for 15 min) expressed no or little MHC class II
(Fig. S4B). The recovered moDCs were then washed with ice-cold
PBS, and lysed with buffer containing a proteinase inhibitor
cocktail (Sigma, St Louis, USA). 30 mg of total cell lysate protein
aliquots were loaded onto 12% polyacrylamide gels and subjected
to SDS-PAGE analysis. Gels were blotted onto Immobilon P
membranes (Millipore, Bedford, Mass., USA), blocked in Tris-
buffered saline (TBS) containing 0.05% Tween 20 (TBS-T) and
5% milk, and probed with primary mAbs against human Bcl-2,
Bcl-xL (Zymed laboratories Inc., CA, USA, both 1:200 dilution),
phospho-Akt (Ser-473), phospho-c-Raf (Ser338), or rabbit poly-
clonal antibodies to phospho-ASK1 (Thr845) (1:1000, Cell
Signaling, USA), or b-actin (1:1000, Santa Cruz, Ca, USA)
overnight at 4uC. Membranes were then washed and incubated
with horseradish peroxidase-conjugated secondary antibody
(1:5000; Santa Cruz, CA, USA) for 1 h at room temperature.
After washing, membranes were developed with an ECL
enhanced chemiluminescence Western blot kit and exposed to
Hyperfilm (both from Amersham Pharmacia Biotech, Inc.,
Piscataway, N.J., USA) at room temperature. The rabbit
polyclonal anti-p-ASK1(Thr845) Ab was confirmed to detect p-
ASK1 expression of HEK293 cells transfected with human ASK-1
(Fig. S12). Transfection of moDC with siRNA for human ASK1 or
control siRNA (20 mM each, Santa Cruz, USA) was performed as
described [63] by Oligofectamine, followed by protocols according
to manufacturer’s instruction (Invitrogen, Carlsbad, CA, USA).
Day 5–6 moDC were transfected 1 day before pulsing with
immune-complex gp120.
Statistical analysis
Data were presented as mean 6 standard deviations and
analyzed by ANOVA using SPSS 10 software.
Supporting Information
Figure S1 moDC in coculture with autologous activated
CD4 T cells can be identified as a large granular CD3-
negative, DC-SIGN-positive population by flow cytome-
try. (A) After vigorous pipetting and re-suspension of the cells in
the DC-T coculture wells, consistently ,5% of the cells in the
larger and more granular population (gated in R1, left panel)
expressed CD3 (right upper panel). In contrast, consistently.95%
of the smaller and less granular cells (gated in R2) expressed CD3.
Data are representative of 3 experiments. Solid line, anti-CD3;
dashed line, isotype control. (B) more than 90% of R1 population
(gated, left panel) expressed DC-SIGN (right panel), while only
4.3% of R2 cells did so. Therefore, cells in R1 are mostly moDCs,
whereas those in R2 are mostly T cells. Data are representative of
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6 experiments. (C) MoDC which were pulsed with cross-linked
(immune-complex) gp120 and cocultured with autologous activat-
ed CD4 T cells for 2 to 4 days were analyzed for their viability by
AV and PI staining. Results showed that the percentage of
AV(+)PI(2) cells (right lower quadrant) increased from d2 to d3
but decreased from d3 to d4, whereas AV(+)PI(+) cells (right upper
quadrant) increased from d2 to d3, and further increased to d4.
The total AV+ cells (including both AV+PI2 and AV+PI+ cells),
nevertheless, remained relatively consistent between d3 and d4
(58.7% vs 58.4%). This finding is in line with results of Fig. 1C (of
the text) and indicates that as incubation time increases, some cells
at early apoptotic (AV+PI2) phase would become late apoptotic
(AV+PI+) cells. Results are representative of 3 experiments.
(TIF)
Figure S2 EndoH treatment of recombinant gp120
abolished its binding to moDC. (A) Recombinant gp120ADA
supernatant was treated overnight with 25 KU of EndoH/ml as
described (Hong PWP et al, J Virol 2002;76:12855–12865), and
the treated and the untreated gp120ADA supernatant were
subjected to Western blot assay by polyclonal rabbit anti-gp120
Ab (Sino Biological Inc). The untreated gp120 had a
MW<120 kDa, whereas the EndoH-treated one had
MW<80 kDa. (B) EndoH-untreated recombinant gp120ADA and
gp120HXBc2 were cross-linked with anti-His or anti-FLAG Ab, as
described in materials and methods, and subsequently subjected to
native non-reducing Western blot analysis (as described by Hong
PWP et al, J Virol 2002;76:12855–12865). The cross-linked gp120
had MW<410–420 kDa (lane 1 & 2, left panel), and the MW of
monomeric gp120 was <120 kDa (lane 3 & 4). The cross-linked
deglycosylated (EndoH-treated) gp120 were in lanes 5 & 6 (<330–
340 kDa), and monomeric EndoH-treated gp120 were in lanes 7
& 8 (<80 kDa). In a separate gel, the MW of anti-His or anti-
FLAG Abs used for cross linking (as detected by goat polyclonal
anti-mouse IgG Ab; Genscript, USA) was <170–180 kDa (lane 9).
Flow cytometry of EndoH-treated or -untreated cross-linked
gp120ADA binding on moDC was shown in the right panel.
Briefly, 56105 moDC were fixed with formalin first and incubated
by EndoH-treated or -untreated gp120ADA cross-linked by mouse
anti-His Ab for 30 min. After wash cells were incubated with the
FITC-conjugated goat polyclonal anti-mouse IgG antibody
(BioLegend) for 30 min. Isotype control antibody (black line) was
goat control Ig (Abcam). Data are representative of 3 independent
experiments.
(TIF)
Figure S3 Anti-DC-SIGN mAbs inhibited binding of
HIV-1 gp120 and uptake of HIV-1 virions by DC-SIGN
transfectants which bound soluble ICAM-3-Fc chimeric
recombinant protein. (A) DC-SIGN-transfected or mock-
transfected 293 cells were pre-treated without (as a control) or
with anti-DC-SIGN mAb clones 120612 and DC28, individually
or in combination (10 mg/ml each), for 1 h at 4uC. After wash,
cells were incubated for 1 h at 4uC with 10 mg/ml recombinant
gp120ADA cross-linked by FITC-conjugated anti-His mAb, or with
recombinant gp120IIIB and gp120MN cross-linked by 2G12 mAb
(NIH AIDS Research and Reference Reagent Program) as
indicated, washed and analysed by flow cytometry. Shaded area,
binding of recombinant gp120; solid line, gp120 binding after pre-
treatment with anti-DC-SIGN mAb(s); dashed line, binding of
gp120 to mock transfectants. Note that the most effective
inhibition, though still incomplete, of gp120 binding was seen
with the combination of anti-DC-SIGN mAbs, while DC28 was
more effective than 120612 when tested individually. Data are
representative of 3 experiments. (B) 56105 DC-SIGN-transfected
(Tf) or mock-transfected THP-1 cells were incubated with HIV-
189.6 (p24 = 1.5 ng; from NIH AIDS Research and Reference
Reagent Program) in a total volume of 400 ml for 3 hours at 37uC
to allow cellular adsorption of the virus and viral replication. The
cells were pre-treated without or with a combination of anti-DC-
SIGN mAbs (clone 120612 plus DC28) at room temperature for
30 minutes prior to exposure to virus supernatant and during
subsequent culture. Cells were then washed extensively to remove
unbound virus, lysed in 0.5% Triton X-100, and the lysates were
subjected to analysis using p24 ELISA kits (Coulter, FL, USA).
Data are expressed as mean6SD of 3 experiments.
(TIF)
Figure S4 CD40L-transfected L cells expressed CD40L
with levels similar to activated CD4 T cells, and gp120-
DCs can be recovered from adherent CD40 ligand-
transfected (CD40L Tf) cells. (A) Activated CD4 T cells
(treated with 10 mg/ml PMA and 1 mg/ml ionomycin for 24 h) or
CD40L Tf cells were incubated with 10 mg/ml anti-CD40L mAb
(Alexis, Lausen, Switzerland) or isotype control and analyzed by
flow cytometry using a FACSCalibur (Becton Dickinson, San
Diego, CA, USA). Solid line, anti-CD40L mAb; dashed line,
isotype control. Data are representative of 4 experiments. (B) Cells
recovered from DC+CD40L Tf coculture expressed high levels of
HLA-DR. Briefly, moDCs were treated with cross-linked recom-
binant gp120ADA and subsequently co-cultured with CD40L Tf
cells for 3 days. The non- and weakly-adherent cells were
harvested by pipetting and resuspension and subsequently labeled
by anti-HLA-DR mAb (R & D systems) and subjected to flow
cytometric analysis. Virtually all the recovered (non-adherent) cells
expressed HLA-DR (left panel). The remaining adherent cells that
had been detached with EDTA expressed little HLA-DR (right
panel), confirming that virtually all DCs had been recovered for
analysis. Data are representative of 3 experiments, and results
were similar for the cocultures of CD40L Tf and DCs pulsed with
gp120ADA or HIV-1(+) serum (not shown).
(TIF)
Figure S5 Trypan blue staining of moDC that were
treated with anti-His cross-linked gp120ADA or anti-His
mAb alone (control DC) and recovered from co-culture
with CD40L Tf after 3 days. Data represent mean 6 SD from
3 experiments; ***p,0.001.
(TIF)
Figure S6 Soluble recombinant ICAM-3-Fc chimeric
protein (sICAM-3) bound to DC-SIGN-transfectants
and pre-treatment with receptor antagonist mAbs alone
did not sensitize DC for CD40L-mediated apoptosis. (a)
DC-SIGN-transfected or mock-transfected 293 cells were incu-
bated with 10 mg/ml soluble ICAM-3-Fc chimeric protein (cross-
linked with anti-His mAb) or with anti-His mAb alone, for 1 h at
4uC. After wash, cells were incubated with FITC-conjugated
rabbit-anti-mouse antibody (DAKO, Denmark) for 1 h at 4uC and
analysed by flow cytometry. Solid line, cross-linked sICAM-3-Fc;
dashed line, anti-His mAb. Data are representative of 3
experiments. (b) moDC were treated for 24 h with combinations
of anti-His plus anti-FLAG mAbs (panel A) which were used to
cross-link the gp120, anti-CD4 (clone RPA-T4) plus anti-CCR5
(clone 2D7) mAbs (panel B), anti-CD4 plus anti-CXCR4 (clone
12G5) mAbs (panel C), anti-DC-SIGN (clones 120612 plus DC28)
mAbs (panel D), or with cross-linked gp120ADA or gp120HXBc2
respectively (cross-linked with anti-His or anti-FLAG mAbs; panel
E and F respectively), and co-cultured with CD40L transfectants
for 3 days. All antibodies and gp120 were used at 25 nM and
50 nM each. Flow cytometric analysis confirmed little apoptosis of
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the mAb-treated moDC (panels A–D) compared to the gp120-DC
(panels E & F). Data are representative of 3 experiments. In
further experiments, treatment with a combination of the three
anti-CD4/CCR5/CXCR4 mAbs did not induce CD40L Tf-
mediated DC apoptosis either (data not shown).
(TIF)
Figure S7 moDCs treated with HIV(+) sera can be
identified as a distinctly smaller-sized CD3-negative
population compared to control moDC. MoDC were
treated with normal AB serum (Control DC) or with HIV-1(+)
serum [HIV(+) serum-DC] with viral loads .400,000/ml (Table
S1) for 24 h, and co-cultured with autologous activated CD4 T
cells for 3 d. Cells were then harvested and subjected to flow
cytometric analysis. In contrast to control moDC (R1 in left panel;
compare to Fig. S1A), the sera-treated moDCs were identified as a
distinctly smaller CD3-negative population (round circle in the
middle panel), indicative of the induction of apoptosis. Data are
representative of 3 experiments.
(TIF)
Figure S8 Immunoprecipitation (IP) of gp120 reduced
p24 levels in supernatants of in vitro propagated live
virus. IP was performed by adding 10 mg/ml each of anti-gp120
mAbs 2G12 and IgG1b12 (NIH AIDS Research and Reference
Reagent Program) into 2 ml supernatants of in vitro propagated HIV-
1BaL (BaL) or HIV-1IIIB (IIIB) virus. Solutions were mixed on ice for
1 hour and 20 mg of protein A sepharose (Sigma-Aldrich, St Louis,
USA) in PBS was added for additional 1 hour. Protein A beads were
then removed by centrifugation. Two further rounds of protein A
sepharose depletion were similarly performed before retrieval of the
depleted serum for determination of p24 levels by ELISA kit (Coulter,
FL, USA). Data are expressed as mean 6 SD of 3 experiments.
(TIF)
Figure S9 Pre-treatment with mannan abolished
CD40L-mediated apoptosis of moDC pulsed by HIV
serum and FcR blocking of moDC enhanced the CD40L-
mediated death of HIV serum-pulsed DC. (A & B) 50KU of
EndoH (in 100 ml) and 100 ml of protease inhibitors (cOmplete
ULTRA tablet, EDTA-free; from Roche; in order to protect the
integrity of EndoH after addition into the serum) were mixed into
1 ml of HIV(+) serum (with a viral titer .400,000/ml; Table S1)
for 5–10 minutes before being ultra-centrifuged to obtain the 100–
1000 kDa fraction (as described in ‘‘materials and methods’’). DC
were then pulsed by such EndoH-treated or untreated HIV serum
(100–1000 kDa fraction) after being pre-treated with or without
mannan or FcR blocking reagent (as described in Fig. 2E of the
text), or anti-DC-SIGN mAbs, and subsequently cocultured with
CD40L Tf. After 3 days, DC were detached and recovered, and
underwent AV/PI staining. DC pulsed by normal AB serum were
used a control. Results revealed that DC pulsed by EndoH-treated
HIV(+) serum had significant reduction in CD40L-mediated
apoptosis (down to control levels), when compared with cells
pulsed by EndoH-untreated HIV serum. Furthermore, consistent-
ly as in the use of recombinant gp120, FcR blocking itself did not
induce excessive apoptosis of control DC (which were pulsed with
normal AB serum), and FcR blockade of DC prior to pulse with
HIV serum further increased the extent of CD40L-mediated
apoptosis (P,0.05, in comparison to no FcR blockade). In
addition, compared with DC-SIGN blockade which partially
prevented DC death (p,0.05 compared to DC without DC-SIGN
blockade), pre-treatment of DC with mannan further reduced the
CD40L-mediated DC apoptotic (*p,0.05 compared to DC-SIGN
blockade). Representative of 3 independent experiments was
shown in A, and the % of total AV(+) cells in each condition was
expressed as mean 6 SD in B.
(TIF)
Figure S10 Freshly-isolated DC-SIGN(+) cells from
blood expressed CD40 and CD11c. DC-SIGN(+) cells (gated
in the left panel) were isolated from the CD14(+) subset of PBMCs as
described in the Materials and Methods. Cells were incubated with
FITC-conjugated anti-CD40 or anti-CD11c mAbs (BD PharMin-
gen, CA, USA) and analyzed by flow cytometry (middle and right
panels). In line with a previous report (Engering A et al, Blood
2002;100:1780–1786), essentially all DC-SIGN(+) cells expressed
CD11c and CD40. Data are representative of 3 experiments.
(TIF)
Figure S11 Cross-linked gp120 modulates the expres-
sion of surface molecules typically associated with DC
maturation in a DC-SIGN-dependent manner but is
inefficient compared with maturation by conventional
factors. (A) 16106 moDC were cultured for 24 h at 37uC in the
presence of 10 mg/ml monomeric gp120ADA (left column), anti-
His cross-linked gp120ADA (10 mg/ml, middle column), or anti-His
cross-linked gp120ADA with DC-SIGN blockade (10 mg/ml each
of anti-DC-SIGN mAbs clone 12612 and DC28; right column).
Results indicated that immune-complex gp120 indeed could
induce phenotypic maturation of moDC, as manifested by clear
upregulation of CD80, CD83, CD86, and CCR7, and downreg-
ulation of CCR5. Such modulation could be in part prevented by
pre-treatment by anti-DC-SIGN mAbs (right column). The
change in CD40 and HLA-DR expression was not as remarkable
as others. Data are representative of 5 experiments. (B) moDC
were treated with dimeric (cross-linked) gp120 (10 mg/ml;
immune-complex/gp120 or IC/gp120) or conventional DC
maturation factors as similarly described by Shan M et al, PLoS
Pathogens 2007;3:1637–1650, ie,, exposure to a mixture of 10 ng/
ml LPS, 25 ng/ml TNFa, 10 ng/ml IL-1b, and simultaneous
coculture with CD40L (as described in ‘‘materials and methods’’)
for 24 h. DCs with no treatment were used as a control (control
DCs). After treatment, DC were subjected to flow cytometric
analysis of surface expression of costimulatory and maturation
markers. Compared with conventional maturation, IC/gp120
induced inefficient modulation of moDCs in the upregulation of
CD80, CD86, CD83, CCR7, as well as in the downregulation of
CCR5. In contrast, the upregulation of MHC class II appeared to be
less affected. Data are representative of 3 independent experiments.
(TIF)
Figure S12 Expression of the anti-apoptotic Bcl-2 and
Bcl-xL was reduced after co-culture of gp120-primed
moDCs with CD40L transfectants, and rabbit polyclonal
anti-ASK1 Ab detected p-ASK1 expression in ASK1-
transfected cells. (A) moDC were treated with cross-linked
gp120ADA (gp120-DC) or anti-His mAb (control DC) followed by
co-culture with CD40L Tf. After 3 d, DC were harvested from
and lysed, and cellular protein was subjected to western blotting
for the indicated proteins. Data are representative of 3
experiments. (B) moDC were treated with HIV-1(+) serum
(RNA copy number.400,000/ml) with or without pre-treatment
by anti-DC-SIGN mAbs, as described in ‘‘materials and
methods’’, prior to coculture with CD40L transfectants as
described in panel A, and cellular protein was extracted and
subjected to western blotting for the indicated proteins. Data are
representative of 3 experiments. (C) Human ASK1 (Ichijo H et al,
Science 1997;275:90–94) was generated in pcDNA3 vector, as
described (Won M et al, Cell Death and Differentiation 2010;17:1830–
1841), and transiently transfected into HEK293 cells by
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lipofecatmine PLUS, according to manufacturer’s instructions.
After <36 hours, cell were lysed and subjected to Western blot
assay with rabbit polyclonal anti-ASK1 Ab (Phospho-ASK1
(Thr845) antibody, #3765, Cell Signaling, USA). Results
confirmed ASK1 expression with a molecular weight <160 kDa,
which served as a positive control for p-ASK1 expression in
Fig. 7A. Data are representative of 3 independent experiments.
(TIF)
Table S1 Viral RNA copy numbers in the sera of HIV-1
infected individuals used for this study. Patient viral RNA
copy numbers were retrieved from archived information. The
following individual or pooled patient (#) samples were used to
obtain the data shown in the respective figures: Figures 3A #9; 3B
#7–10; 3C #10; 3D #5–7 and #10; 4A #1–4 and 5–7; 4B #6,
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